Medicus Pharma Ltd. Common Stock

Medicus Pharma Ltd. Common Stock

MDCX - Insider Information

Get informed when a big investor buys or sells

+ Follow
Market Cap$118.37M
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Medicus Pharma Ltd. Common StockMedicus Pharma Ltd. Common Stock-0.1----
$1.00

Target Price by Analysts

53.5% downsideMedicus Pharma Ltd. Common Stock Target Price DetailsTarget Price
$0.27

Current Fair Value

87.3% downside

Overvalued by 87.3% based on the discounted cash flow analysis.

Insider Trades

Loading insider trades…

Congress Trades

Loading congress trades…

Share Statistics

Market cap$118.37 Million
Enterprise Value-
Earnings per Share$-1.96
Beta-0.61
Outstanding Shares55,055,225

Return

Return on EquityNaN%ROE
Return on AssetsNaN%
Return on Invested CapitalNaN%

Valuation & Multiples

P/E Ratio-0.06P/E Ratio
PEG-0.16PEG
Price to Sales-Price to Sales
Price to Book Ratio-Price to Book Ratio
Enterprise Value to Revenue-
Enterprise Value to EBIT-
Enterprise Value to Net Income-
Total Debt to Enterprise-
Debt to Equity-Debt to Equity

Revenue Sources

No data

Last Earnings Call

Report Date
August 12, 2026
EPS Estimate
$-6.38
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Next Earnings Call

Expected Date
November 13, 2026
EPS Estimate
$-6.68
Consensus analyst estimate
Revenue Estimate
-
Consensus analyst estimate

Institutional Put/Call Ratio

Compares institutional put options with call options. At 0.00, the ratio is below 1, so institutions hold more calls than puts.

Put/Call Ratio0.00000%
Total Calls-
Total Puts-

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %4.76%▼ 3.09%
Total Invested$1.18M▲ 10.82%
Investors Holding22▲ 2.00%

About Medicus Pharma Ltd. Common Stock

16 employees
CEO: Raza Bokhari

Medicus Pharma Ltd., a biotechnology and life sciences enterprise, is dedicated to expediting the progression of innovative and groundbreaking medical treatments through their clinical development phases. A primary focus for the company ...